InMode Ltd.

Good day and welcome to InMode's first quarter 2025 earnings results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Mary Segal, CEO of MSIR. Please go ahead.

Thank you, operator, and to everyone for joining us today. Welcome to InMode's first quarter 2025 earnings call. Before we begin, I would like to remind our listeners that certain information provided on this call may contain forward-looking statements. and the safe harbor statement outlined in today's earnings release also pertains to this call. If you have not received a copy of the release, please go to the investor relations section of the company's website. Changes in business, competitive, technological, regulatory, and other factors could cause actual results to differ materially from these expressed by the forward-looking statements made today. Our historical results are not necessarily indicative of future performance. As such, we can give no assurance as to the accuracy of our forward-looking statements and assume no obligation to update them except as required by law. With that, I'd like to turn the call over to Moshe Mizrachi, CEO. Moshe, please go ahead.

Thank you, Mary, and to everyone for joining us. With me today, are Dr. Michael Kreindel, our Co-Founder and Chief Technology Officer, Yair Malka, our Chief Financial Officer, and Raphael Likerman, our VP of Finance. Following our prepared remark, we will all be available to answer your question. The medical aesthetic market continues to face headwinds driven primarily by ongoing macroeconomic uncertainty and soft consumer demand. Effective elective procedures, particularly in the surgical aesthetic segment, are often among the first to be pulled back during period of economic slowdown. And we have seen that reflected in recent quarters across the last two years. Patients are deferring treatment and providers are taking a more cautious approach to capital investment. Despite this near-term pressure, we remain confident in the fundamentals of our business. Consumer interest in minimally invasive aesthetic procedures continues to be solid. And we believe demand will return as macro conditions stabilize and consumer confidence start to grow. We made a deliverable decision as a company not to cut corners, not to reduce our workforce, and to remain committed to leading the industry. Because we believe that when the market rebound and demand will return, we will be ready to lead and benefit as we have in the past following major challenges. Later this year, we plan to unveil a new platform designed for the wellness market, further expanding the depth of our product portfolio. This addition reflects our ongoing strategy to diversify our offering and tap into a new segment. We look forward to sharing more detail as we approach the official launch. As stated in the press release, we are proud to have completed our fifth share purchase program this month. Earlier this month, we purchased 6.95 million shares, totaling $127 million. In fact, over the past 12 months alone, we have returned more than $412 million to the shareholders through share purchase representing approximately 27% of our total capital. Finally, despite the macroeconomic challenges, we believe InMod is uniquely positioned to lead through this cycle with a strong balance sheet, a diversified portfolio, and industry-leading technology. Now, I would like to turn the call over to Yair, our Chief Financial Officer. Yair.